364 related articles for article (PubMed ID: 26644412)
1. Gemtuzumab Ozogamicin Reduces Relapse Risk in FLT3/ITD Acute Myeloid Leukemia: A Report from the Children's Oncology Group.
Tarlock K; Alonzo TA; Gerbing RB; Raimondi SC; Hirsch BA; Sung L; Pollard JA; Aplenc R; Loken MR; Gamis AS; Meshinchi S
Clin Cancer Res; 2016 Apr; 22(8):1951-7. PubMed ID: 26644412
[TBL] [Abstract][Full Text] [Related]
2. Gemtuzumab ozogamicin in children and adolescents with de novo acute myeloid leukemia improves event-free survival by reducing relapse risk: results from the randomized phase III Children’s Oncology Group trial AAML0531.
Gamis AS; Alonzo TA; Meshinchi S; Sung L; Gerbing RB; Raimondi SC; Hirsch BA; Kahwash SB; Heerema-McKenney A; Winter L; Glick K; Davies SM; Byron P; Smith FO; Aplenc R
J Clin Oncol; 2014 Sep; 32(27):3021-32. PubMed ID: 25092781
[TBL] [Abstract][Full Text] [Related]
3. Gemtuzumab Ozogamicin Improves Event-Free Survival and Reduces Relapse in Pediatric
Pollard JA; Guest E; Alonzo TA; Gerbing RB; Loken MR; Brodersen LE; Kolb EA; Aplenc R; Meshinchi S; Raimondi SC; Hirsch B; Gamis AS
J Clin Oncol; 2021 Oct; 39(28):3149-3160. PubMed ID: 34048275
[TBL] [Abstract][Full Text] [Related]
4. A Phase I Study of Reduced-Intensity Conditioning and Allogeneic Stem Cell Transplantation Followed by Dose Escalation of Targeted Consolidation Immunotherapy with Gemtuzumab Ozogamicin in Children and Adolescents with CD33+ Acute Myeloid Leukemia.
Zahler S; Bhatia M; Ricci A; Roy S; Morris E; Harrison L; van de Ven C; Fabricatore S; Wolownik K; Cooney-Qualter E; Baxter-Lowe LA; Luisi P; Militano O; Kletzel M; Cairo MS
Biol Blood Marrow Transplant; 2016 Apr; 22(4):698-704. PubMed ID: 26785332
[TBL] [Abstract][Full Text] [Related]
5. CD33 Expression and Its Association With Gemtuzumab Ozogamicin Response: Results From the Randomized Phase III Children's Oncology Group Trial AAML0531.
Pollard JA; Loken M; Gerbing RB; Raimondi SC; Hirsch BA; Aplenc R; Bernstein ID; Gamis AS; Alonzo TA; Meshinchi S
J Clin Oncol; 2016 Mar; 34(7):747-55. PubMed ID: 26786921
[TBL] [Abstract][Full Text] [Related]
6. Correlation of CD33 expression level with disease characteristics and response to gemtuzumab ozogamicin containing chemotherapy in childhood AML.
Pollard JA; Alonzo TA; Loken M; Gerbing RB; Ho PA; Bernstein ID; Raimondi SC; Hirsch B; Franklin J; Walter RB; Gamis A; Meshinchi S
Blood; 2012 Apr; 119(16):3705-11. PubMed ID: 22378848
[TBL] [Abstract][Full Text] [Related]
7. Outcome of FLT3-ITD-positive acute myeloid leukemia: impact of allogeneic stem cell transplantation and tyrosine kinase inhibitor treatment.
Fleischmann M; Schnetzke U; Schrenk KG; Schmidt V; Sayer HG; Hilgendorf I; Hochhaus A; Scholl S
J Cancer Res Clin Oncol; 2017 Feb; 143(2):337-345. PubMed ID: 27778197
[TBL] [Abstract][Full Text] [Related]
8. ABCB1 SNP predicts outcome in patients with acute myeloid leukemia treated with Gemtuzumab ozogamicin: a report from Children's Oncology Group AAML0531 Trial.
Rafiee R; Chauhan L; Alonzo TA; Wang YC; Elmasry A; Loken MR; Pollard J; Aplenc R; Raimondi S; Hirsch BA; Bernstein ID; Gamis AS; Meshinchi S; Lamba JK
Blood Cancer J; 2019 May; 9(6):51. PubMed ID: 31113932
[TBL] [Abstract][Full Text] [Related]
9. Mobilization-driven postconsolidation therapy in elderly patients with acute myeloid leukemia: feasibility and efficacy of autologous stem cell transplantation versus low-dose gemtuzumab ozogamicin.
Capelli D; Chiarucci M; Poloni A; Saraceni F; Mancini G; Trappolini S; Troiani E; Montanari M; Scortechini I; Offidani M; Rupoli S; Scortechini AR; Gini G; Discepoli G; Leoni P; Olivieri A
Biol Blood Marrow Transplant; 2014 Sep; 20(9):1399-406. PubMed ID: 24880020
[TBL] [Abstract][Full Text] [Related]
10. Outcome of Childhood Acute Myeloid Leukemia With FLT3-ITD Mutation: The Experience of Children's Cancer Hospital Egypt, 2007-17.
Semary SF; Hammad M; Soliman S; Yassen D; Gamal M; Albeltagy D; Hamdy N; Mahmoud S
Clin Lymphoma Myeloma Leuk; 2020 Aug; 20(8):e529-e541. PubMed ID: 32473792
[TBL] [Abstract][Full Text] [Related]
11. Mild chronic graft-versus-host disease may alleviate poor prognosis associated with FLT3 internal tandem duplication for adult acute myeloid leukemia following allogeneic stem cell transplantation with myeloablative conditioning in first complete remission: a retrospective study.
Nasilowska-Adamska B; Czyz A; Markiewicz M; Rzepecki P; Piatkowska-Jakubas B; Paluszewska M; Dzierzak-Mietla M; Solarska I; Borg K; Prochorec-Sobieszek M; Szydlo R; Lewandowski K; Skotnicki A; Jedrzejczak WW; Kyrcz-Krzemien S; Komarnicki M; Warzocha K
Eur J Haematol; 2016 Mar; 96(3):236-44. PubMed ID: 25912052
[TBL] [Abstract][Full Text] [Related]
12. Approval summary: gemtuzumab ozogamicin in relapsed acute myeloid leukemia.
Bross PF; Beitz J; Chen G; Chen XH; Duffy E; Kieffer L; Roy S; Sridhara R; Rahman A; Williams G; Pazdur R
Clin Cancer Res; 2001 Jun; 7(6):1490-6. PubMed ID: 11410481
[TBL] [Abstract][Full Text] [Related]
13. CD33 Splicing Polymorphism Determines Gemtuzumab Ozogamicin Response in De Novo Acute Myeloid Leukemia: Report From Randomized Phase III Children's Oncology Group Trial AAML0531.
Lamba JK; Chauhan L; Shin M; Loken MR; Pollard JA; Wang YC; Ries RE; Aplenc R; Hirsch BA; Raimondi SC; Walter RB; Bernstein ID; Gamis AS; Alonzo TA; Meshinchi S
J Clin Oncol; 2017 Aug; 35(23):2674-2682. PubMed ID: 28644774
[TBL] [Abstract][Full Text] [Related]
14. Autologous transplantation gives encouraging results for young adults with favorable-risk acute myeloid leukemia, but is not improved with gemtuzumab ozogamicin.
Fernandez HF; Sun Z; Litzow MR; Luger SM; Paietta EM; Racevskis J; Dewald G; Ketterling RP; Rowe JM; Lazarus HM; Tallman MS
Blood; 2011 May; 117(20):5306-13. PubMed ID: 21415269
[TBL] [Abstract][Full Text] [Related]
15. AAML03P1, a pilot study of the safety of gemtuzumab ozogamicin in combination with chemotherapy for newly diagnosed childhood acute myeloid leukemia: a report from the Children's Oncology Group.
Cooper TM; Franklin J; Gerbing RB; Alonzo TA; Hurwitz C; Raimondi SC; Hirsch B; Smith FO; Mathew P; Arceci RJ; Feusner J; Iannone R; Lavey RS; Meshinchi S; Gamis A
Cancer; 2012 Feb; 118(3):761-9. PubMed ID: 21766293
[TBL] [Abstract][Full Text] [Related]
16. Hematopoietic stem cell transplant following remission induction chemotherapy including gemtuzumab ozogamicin is a feasible and effective treatment option in elderly patients with acute myeloid leukemia.
Eom KS; Kim HJ; Cho BS; Choi SM; Lee DG; Lee SE; Yahng SA; Kim YJ; Lee S; Min CK; Cho SG; Kim DW; Lee JW; Park CW; Min WS
Leuk Lymphoma; 2011 Dec; 52(12):2321-8. PubMed ID: 22023488
[TBL] [Abstract][Full Text] [Related]
17. Efficacy and resistance of gemtuzumab ozogamicin for acute myeloid leukemia.
Takeshita A
Int J Hematol; 2013 Jun; 97(6):703-16. PubMed ID: 23709007
[TBL] [Abstract][Full Text] [Related]
18. Haematopoietic cell transplantation with and without sorafenib maintenance for patients with FLT3-ITD acute myeloid leukaemia in first complete remission.
Brunner AM; Li S; Fathi AT; Wadleigh M; Ho VT; Collier K; Connolly C; Ballen KK; Cutler CS; Dey BR; El-Jawahri A; Nikiforow S; McAfee SL; Koreth J; Deangelo DJ; Alyea EP; Antin JH; Spitzer TR; Stone RM; Soiffer RJ; Chen YB
Br J Haematol; 2016 Nov; 175(3):496-504. PubMed ID: 27434660
[TBL] [Abstract][Full Text] [Related]
19. Impact of FLT3 internal tandem duplication on the outcome of related and unrelated hematopoietic transplantation for adult acute myeloid leukemia in first remission: a retrospective analysis.
Brunet S; Labopin M; Esteve J; Cornelissen J; Socié G; Iori AP; Verdonck LF; Volin L; Gratwohl A; Sierra J; Mohty M; Rocha V
J Clin Oncol; 2012 Mar; 30(7):735-41. PubMed ID: 22291086
[TBL] [Abstract][Full Text] [Related]
20. Gemtuzumab ozogamicin as postconsolidation therapy does not prevent relapse in children with AML: results from NOPHO-AML 2004.
Hasle H; Abrahamsson J; Forestier E; Ha SY; Heldrup J; Jahnukainen K; Jónsson ÓG; Lausen B; Palle J; Zeller B;
Blood; 2012 Aug; 120(5):978-84. PubMed ID: 22730539
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]